Romidepsin
Three-drug regimen may reduce relapse risk after transplant for T-cell malignancies
Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.
VIDEO: Romidepsin linked with reduced size, viability of osteosarcoma sarcospheres
TAMPA, Fla. — In a video at the Orthopaedic Research Society Annual Meeting, Emily E. Seiden, BS, discusses romidepsin, which showed promise as a therapeutic to target micrometastases progression in osteosarcoma.
Top in hem/onc: Right to Try vs. Expanded Access, priority review of thyroid cancer drug
Recent data revealed the Right to Try track did not more successfully help oncologists obtain investigational drugs than Expanded Access, which has an extra step of receiving FDA authorization for each patient.
Bristol Myers Squibb withdraws peripheral T-cell lymphoma indication for romidepsin
Bristol Myers Squibb withdrew the indication for romidepsin as treatment for relapsed or refractory peripheral T-cell lymphoma.